{"id":743818,"date":"2013-04-08T09:37:00","date_gmt":"2013-04-08T09:37:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/"},"modified":"2023-03-22T00:04:40","modified_gmt":"2023-03-22T04:04:40","slug":"merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/","title":{"rendered":"Merck to Present New Data on VICTRELIS\u00ae (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM \/ 2013 EASL Annual Meeting"},"content":{"rendered":"<p class=\"bwalignl\">\n      Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n      announced today that two analyses of VICTRELIS (boceprevir) and data<br \/>\n      from Phase II studies of two of Merck\u2019s investigational medicines for<br \/>\n      chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir<br \/>\n      (MK-7009), will be presented at the 2013 International Liver Congress<br \/>\n      (EASL) Annual Meeting. The meeting will take place in Amsterdam from<br \/>\n      April 24-28, 2013.\n    <\/p>\n<p>\n      <b>Key Presentations About VICTRELIS 200 mg Capsules<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Safety And Efficacy Of Boceprevir\/Peginterferon\/Ribavirin (Boc\/P\/R)<br \/>\n        Combination Therapy For Chronic HCV G1 Patients With Compensated<br \/>\n        Cirrhosis: A Meta-Analysis Of Five Phase III Clinical Trials, J.M.<br \/>\n        Vierling et al. Late Breaker. Thursday, April 25, 9:00- 18:00. RAI<br \/>\n        Convention Centre.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Virologic Response Rates Are Similar In Previously Untreated And<br \/>\n        Previously Treated And Relapsed Patients Receiving Boceprevir Triple<br \/>\n        Therapy: A Retrospective Analysis. Bacon, B. et al. Poster 791.<br \/>\n        Friday, April 26, 12:30-14:00. RAI Convention Centre.\n      <\/li>\n<\/ul>\n<p>\n      <b>Key Investigational Compound Presentations<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        High Sustained Viral Response at 12- and 24-week follow-up of MK-5172<br \/>\n        with Pegylated Interferon alfa-2b and Ribavirin (PR) in HCV Genotype 1<br \/>\n        Treatment-na\u00efve Non-cirrhotic Patients. Manns, M. et al. Oral<br \/>\n        Presentation: Friday, April 26, 16:00-18:00, RAI Convention Centre.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        MK-5172 In Combination With Peg-Interferon And Ribavirin Elicits<br \/>\n        Limited Resistance While Demonstrating Robust Efficacy In Treatment<br \/>\n        Na\u00efve Genotype 1 Chronic HCV-Infected Patients. Howe, A. et al. Poster<br \/>\n        1197. Saturday, April 27, 12:30-13:30. RAI Convention Centre.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Sustained Viral Response And Safety Of MK-7009 In Cirrhotic<br \/>\n        Treatment-Experienced Patients With Genotype 1 HCV Infection Who Have<br \/>\n        Failed Previous Pegylated Interferon And Ribavirin Treatment.<br \/>\n        Rodriguez-Torres, M. et al. Oral Presentation. Saturday, April 27,<br \/>\n        8:30-10:30. RAI Convention Centre.\n      <\/li>\n<\/ul>\n<p>\n      &#8220;We are pleased to present new data on VICTRELIS that will help inform<br \/>\n      health care professionals as they consider the use of VICTRELIS in<br \/>\n      appropriate patients,&#8221; said Eliav Barr, M.D., vice president, Infectious<br \/>\n      Diseases, Project Leadership and Management, Merck Research<br \/>\n      Laboratories. &#8220;Merck is committed to helping reduce the burden of this<br \/>\n      serious disease worldwide. We look forward to sharing our new data about<br \/>\n      VICTRELIS and Merck&#8217;s investigational medicines for chronic hepatitis C<br \/>\n      with the global scientific community.&#8221;\n    <\/p>\n<p>\n      MK-5172 is an investigational, once-daily, oral HCV NS3\/4A protease<br \/>\n      inhibitor currently in Phase II development. Vaniprevir is an oral,<br \/>\n      twice-daily HCV NS3\/4A protease inhibitor in Phase III development in<br \/>\n      Japan for the treatment of genotype 1 patients.\n    <\/p>\n<p>\n      The abstracts were published today and can be accessed on the EASL<br \/>\n      website. For program information, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww2.kenes.com%2Fliver-congress%2Fpages%2Fhome.aspx&#038;esheet=50605214&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww2.kenes.com%2Fliver-congress%2Fpages%2Fhome.aspx&#038;index=1&#038;md5=3412a2c9f29e51f1cad51dcf6055435b\">http:\/\/www2.kenes.com\/liver-congress\/pages\/home.aspx<\/a>.\n    <\/p>\n<p>\n      <b>Indications and usage for VICTRELIS<\/b>\n    <\/p>\n<p>\n      VICTRELIS<sup><b>\u00ae<\/b><\/sup> (boceprevir) is indicated for the treatment<br \/>\n      of chronic hepatitis C virus (HCV) genotype 1 (G1) infection, in<br \/>\n      combination with peginterferon alfa and ribavirin (PR), in adult<br \/>\n      patients (18 years and older) with compensated liver disease, including<br \/>\n      cirrhosis, who are previously untreated or who have failed previous<br \/>\n      interferon and ribavirin therapy, including prior null responders,<br \/>\n      partial responders, and relapsers.\n    <\/p>\n<p>\n      The following points should be considered when initiating VICTRELIS for<br \/>\n      treatment of chronic HCV infection:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        VICTRELIS <span class=\"bwuline\">must not<\/span> be used as monotherapy<br \/>\n        and should only be used in combination with PR.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The efficacy of VICTRELIS has not been studied in patients who have<br \/>\n        previously failed therapy with a treatment regimen that includes<br \/>\n        VICTRELIS or other HCV NS3\/4A protease inhibitors.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poorly interferon responsive patients who were treated with VICTRELIS<br \/>\n        in combination with PR have a lower likelihood of achieving a<br \/>\n        sustained virologic response (SVR), and a higher rate of detection of<br \/>\n        resistance-associated substitutions upon treatment failure, compared<br \/>\n        to patients with a greater response to PR.\n      <\/li>\n<\/ul>\n<p>\n      <b>Important safety information about VICTRELIS<\/b>\n    <\/p>\n<p>\n      All contraindications to PR also apply since VICTRELIS must be<br \/>\n      administered with PR. Because ribavirin may cause birth defects and<br \/>\n      fetal death, VICTRELIS in combination with PR is contraindicated in<br \/>\n      pregnant women and in men whose female partners are pregnant. Avoid<br \/>\n      pregnancy in female patients and female partners of male patients.<br \/>\n      Patients must have a negative pregnancy test prior to therapy; have<br \/>\n      monthly pregnancy tests; and use 2 or more forms of effective<br \/>\n      contraception during treatment and for at least 6 months after treatment<br \/>\n      has concluded. One of these forms of contraception can be a combined<br \/>\n      oral contraceptive product containing at least 1 mg of norethindrone.<br \/>\n      Oral contraceptives containing lower doses of norethindrone and other<br \/>\n      forms of hormonal contraception have not been studied or are<br \/>\n      contraindicated.\n    <\/p>\n<p>\n      VICTRELIS is contraindicated in patients with a history of a<br \/>\n      hypersensitivity reaction to VICTRELIS. VICTRELIS is contraindicated in<br \/>\n      coadministration with drugs that are highly dependent on CYP3A4\/5 for<br \/>\n      clearance, and for which elevated plasma concentrations are associated<br \/>\n      with serious and\/or life-threatening events. VICTRELIS is also<br \/>\n      contraindicated in coadministration with potent CYP3A4\/5 inducers, where<br \/>\n      significantly reduced VICTRELIS plasma concentrations may be associated<br \/>\n      with reduced efficacy. Drugs that are contraindicated with VICTRELIS<br \/>\n      include: alfuzosin, carbamazepine, phenobarbital, phenytoin, rifampin,<br \/>\n      dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride,<br \/>\n      St. John\u2019s Wort (hypericum perforatum), lovastatin, simvastatin,<br \/>\n      drospirenone, <i>Revatio<\/i><sup>\u00ae<\/sup> (sildenafil) or <i>Adcirca<\/i><sup>\u00ae<\/sup><br \/>\n      (tadalafil) (when used for the treatment of pulmonary arterial<br \/>\n      hypertension), pimozide, triazolam, and orally administered midazolam.\n    <\/p>\n<p>\n      Anemia and\/or Neutropenia \u2013 The addition of VICTRELIS to PR is<br \/>\n      associated with an additional decrease in hemoglobin concentrations<br \/>\n      compared with PR alone and\/or may result in worsening of neutropenia<br \/>\n      associated with PR therapy alone. Dose reduction or discontinuation of<br \/>\n      peginterferon alfa and\/or ribavirin may be required. If peginterferon<br \/>\n      alfa or ribavirin is permanently discontinued, VICTRELIS must also be<br \/>\n      discontinued. Dose reduction of VICTRELIS is not recommended. VICTRELIS<br \/>\n      must not be administered in the absence of PR.\n    <\/p>\n<p>\n      Complete blood count (with white blood cell differential counts) must be<br \/>\n      conducted in all patients prior to initiating combination therapy with<br \/>\n      VICTRELIS. Complete blood counts should be obtained at Treatment Weeks<br \/>\n      2, 4, 8, and 12, and should be monitored closely at other time points,<br \/>\n      as clinically appropriate. Serious acute hypersensitivity reactions (eg,<br \/>\n      urticaria, angioedema) have been observed during combination therapy<br \/>\n      with VICTRELIS and PR. If such an acute reaction occurs, combination<br \/>\n      therapy should be discontinued and appropriate medical therapy<br \/>\n      immediately instituted.\n    <\/p>\n<p>\n      The most commonly reported adverse reactions (>35%) in clinical trials<br \/>\n      in adult patients receiving the combination of VICTRELIS with PR were:<br \/>\n      fatigue, anemia, nausea, headache, and dysgeusia. Of these commonly<br \/>\n      reported adverse reactions, fatigue, anemia, nausea, and dysgeusia<br \/>\n      occurred at rates \u22655% above the rates for PR alone in either clinical<br \/>\n      study. The incidence of these adverse reactions in previously untreated<br \/>\n      subjects that were treated with combination therapy with VICTRELIS<br \/>\n      compared with PR alone were: fatigue (58% vs 59%), anemia (50% vs 30%),<br \/>\n      nausea (46% vs 42%), and dysgeusia (35% vs 16%), respectively. The<br \/>\n      incidence of these adverse reactions in previous treatment failure<br \/>\n      patients that were treated with combination therapy with VICTRELIS<br \/>\n      compared with PR alone were: fatigue (55% vs 50%), anemia (45% vs 20%),<br \/>\n      nausea (43% vs 38%), and dysgeusia (44% vs 11%), respectively.\n    <\/p>\n<p>\n      VICTRELIS is a strong inhibitor of CYP3A4\/5 and is partly metabolized by<br \/>\n      CYP3A4\/5. The potential for drug-drug interactions must be considered<br \/>\n      prior to and during therapy.\n    <\/p>\n<p>\n      Please see U.S. prescribing information at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&#038;esheet=50605214&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&#038;index=2&#038;md5=b7eebdc06b3698464f4979743effffcb\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf<\/a>\n    <\/p>\n<p>\n      <b>Merck&#8217;s Global Commitment to Advancing Hepatitis Therapy<\/b>\n    <\/p>\n<p>\n      Merck is committed to building on its strong legacy in the field of<br \/>\n      viral hepatitis by continuing to discover, develop and deliver vaccines<br \/>\n      and medicines to help prevent and treat viral hepatitis. In hepatitis C,<br \/>\n      company researchers developed the first approved therapy for chronic HCV<br \/>\n      in 1991 and the first combination therapy in 1998. In addition to<br \/>\n      ongoing studies for our marketed and investigational medicines for the<br \/>\n      treatment of chronic HCV, extensive research efforts are underway to<br \/>\n      develop additional innovative oral therapies for viral hepatitis<br \/>\n      treatment.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50605214&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=3&#038;md5=394ca62e7705692a61323e3267b6f29e\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50605214&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=4&#038;md5=0953229d0ab0f3505a3bf8891a1425ca\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for VICTRELIS at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&#038;esheet=50605214&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&#038;index=5&#038;md5=75226b118b8a85099a4f57fbb37f18a5\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf<\/b><\/a><b><br \/>\n      and Medication Guide for VICTRELIS at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_mg.pdf&#038;esheet=50605214&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_mg.pdf&#038;index=6&#038;md5=3af9f9aa6c76e9710c9faf4a5940a3fe\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>Revatio<\/b><sup><b>\u00ae<\/b><\/sup><b> and Adcirca<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      are trademarks of their respective owners and are not trademarks of<br \/>\n      Merck &#038; Co., Inc., Whitehouse Station, N.J., USA.<\/b><br \/><b>VICTRELIS<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      is a trademark of Schering Corp., a subsidiary of Merck &#038; Co., Inc.,<br \/>\n      Whitehouse Station, N.J., USA.<\/b>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130408006182r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Caroline Lappetito, 267-305-7369<br \/>Sarra        Herzog, 908-423-6154<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck\u2019s investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting. The meeting will take place in Amsterdam from April 24-28, 2013. Key Presentations About VICTRELIS 200 mg Capsules Safety And Efficacy Of Boceprevir\/Peginterferon\/Ribavirin (Boc\/P\/R) Combination Therapy For Chronic HCV G1 Patients With Compensated Cirrhosis: A Meta-Analysis Of Five Phase III Clinical Trials, J.M. Vierling et al. Late Breaker. Thursday, April 25, 9:00- 18:00. RAI Convention Centre. Virologic Response Rates Are Similar In Previously Untreated And Previously Treated And Relapsed Patients Receiving Boceprevir Triple Therapy: A Retrospective Analysis. Bacon, B. et al. Poster 791. Friday, April 26,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,55,289],"class_list":["post-743818","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Present New Data on VICTRELIS\u00ae (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM \/ 2013 EASL Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Present New Data on VICTRELIS\u00ae (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM \/ 2013 EASL Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck\u2019s investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting. The meeting will take place in Amsterdam from April 24-28, 2013. Key Presentations About VICTRELIS 200 mg Capsules Safety And Efficacy Of Boceprevir\/Peginterferon\/Ribavirin (Boc\/P\/R) Combination Therapy For Chronic HCV G1 Patients With Compensated Cirrhosis: A Meta-Analysis Of Five Phase III Clinical Trials, J.M. Vierling et al. Late Breaker. Thursday, April 25, 9:00- 18:00. RAI Convention Centre. Virologic Response Rates Are Similar In Previously Untreated And Previously Treated And Relapsed Patients Receiving Boceprevir Triple Therapy: A Retrospective Analysis. Bacon, B. et al. Poster 791. Friday, April 26,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:40+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130408006182r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\\\/\",\"name\":\"Merck to Present New Data on VICTRELIS\u00ae (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM \\\/ 2013 EASL Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130408006182r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-04-08T09:37:00+00:00\",\"dateModified\":\"2023-03-22T04:04:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130408006182r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130408006182r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Present New Data on VICTRELIS\u00ae (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM \\\/ 2013 EASL Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Present New Data on VICTRELIS\u00ae (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM \/ 2013 EASL Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Present New Data on VICTRELIS\u00ae (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM \/ 2013 EASL Annual Meeting - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck\u2019s investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting. The meeting will take place in Amsterdam from April 24-28, 2013. Key Presentations About VICTRELIS 200 mg Capsules Safety And Efficacy Of Boceprevir\/Peginterferon\/Ribavirin (Boc\/P\/R) Combination Therapy For Chronic HCV G1 Patients With Compensated Cirrhosis: A Meta-Analysis Of Five Phase III Clinical Trials, J.M. Vierling et al. Late Breaker. Thursday, April 25, 9:00- 18:00. RAI Convention Centre. Virologic Response Rates Are Similar In Previously Untreated And Previously Treated And Relapsed Patients Receiving Boceprevir Triple Therapy: A Retrospective Analysis. Bacon, B. et al. Poster 791. Friday, April 26,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:40+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130408006182r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/","name":"Merck to Present New Data on VICTRELIS\u00ae (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM \/ 2013 EASL Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130408006182r1&sid=sfsite1&distro=nx","datePublished":"2013-04-08T09:37:00+00:00","dateModified":"2023-03-22T04:04:40+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130408006182r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130408006182r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-victrelis-boceprevir-and-investigational-compounds-mk-5172-and-vaniprevir-for-chronic-hepatitis-c-virus-at-the-international-liver-congresstm-2013-easl-annual-me\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Present New Data on VICTRELIS\u00ae (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM \/ 2013 EASL Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"3a9ab715-7066-41f4-bd73-0862e26b5336","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743818\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743818"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}